Alzheimer's Biomarker Tests Development

Regulatory developments were noted for blood-based biomarker tests to detect Alzheimer's disease. These tests represent an emerging tool for early diagnosis. The update was part of a health innovation brief.

FDA Approves Drug for Autoimmune Neuropathies

September 13, 2025 Ti AI ṣe iroyin

The FDA approved a new drug for treating autoimmune neuropathies on September 9, 2025, accompanied by discoveries of new autoantibodies and effective complement inhibitors. This development ends 30 years of limited treatment progress in the field.

Blood test identifies Parkinson's years before symptoms

October 03, 2025 Ti AI ṣe iroyin

Scientists have developed a blood-based test that detects Parkinson's disease up to seven years before the onset of symptoms. The test targets abnormal alpha-synuclein proteins and shows high accuracy in at-risk individuals. This breakthrough could enable earlier treatments to slow disease progression.

Spotlight on tardive dyskinesia and its management

Tardive dyskinesia remains a significant side effect for patients on long-term antipsychotic medications. Recent medical discussions highlight its symptoms, causes, and emerging treatments. Awareness efforts aim to improve early detection and intervention.